Paraneoplastic Endocrine Syndromes: Syndromes resulting from inappropriate production of HORMONES or hormone-like materials by NEOPLASMS in non-endocrine tissues or not by the usual ENDOCRINE GLANDS. Such hormone outputs are called ectopic hormone (HORMONES, ECTOPIC) secretion.Paraneoplastic Syndromes: In patients with neoplastic diseases a wide variety of clinical pictures which are indirect and usually remote effects produced by tumor cell metabolites or other products.Paraneoplastic Syndromes, Nervous System: Degenerative or inflammatory conditions affecting the central or peripheral nervous system that develop in association with a systemic neoplasm without direct invasion by tumor. They may be associated with circulating antibodies that react with the affected neural tissue. (Intern Med 1996 Dec;35(12):925-9)Paraneoplastic Polyneuropathy: A diffuse or multifocal peripheral neuropathy related to the remote effects of a neoplasm, most often carcinoma or lymphoma. Pathologically, there are inflammatory changes in peripheral nerves. The most common clinical presentation is a symmetric distal mixed sensorimotor polyneuropathy. (Adams et al., Principles of Neurology, 6th ed, p1334)Paraneoplastic Cerebellar Degeneration: Cerebellar degeneration associated with a remote neoplasm. Clinical manifestations include progressive limb and GAIT ATAXIA; DYSARTHRIA; and NYSTAGMUS, PATHOLOGIC. The histologic type of the associated neoplasm is usually carcinoma or lymphoma. Pathologically the cerebellar cortex and subcortical nuclei demonstrate diffuse degenerative changes. Anti-Purkinje cell antibodies (anti-Yo) are found in the serum of approximately 50% of affected individuals. (Adams et al., Principles of Neurology, 6th ed, p686)Syndrome: A characteristic symptom complex.Limbic Encephalitis: A paraneoplastic syndrome marked by degeneration of neurons in the LIMBIC SYSTEM. Clinical features include HALLUCINATIONS, loss of EPISODIC MEMORY; ANOSMIA; AGEUSIA; TEMPORAL LOBE EPILEPSY; DEMENTIA; and affective disturbance (depression). Circulating anti-neuronal antibodies (e.g., anti-Hu; anti-Yo; anti-Ri; and anti-Ma2) and small cell lung carcinomas or testicular carcinoma are frequently associated with this syndrome.Paraneoplastic Syndromes, Ocular: Ocular manifestations secondary to various NEOPLASMS in which antibodies to antigens of the primary tumor cross-react with ocular antigens. This autoimmune response often leads to visual loss and other ocular dysfunctions.Endocrine Glands: Ductless glands that secrete HORMONES directly into the BLOOD CIRCULATION. These hormones influence the METABOLISM and other functions of cells in the body.Lambert-Eaton Myasthenic Syndrome: An autoimmune disease characterized by weakness and fatigability of proximal muscles, particularly of the pelvic girdle, lower extremities, trunk, and shoulder girdle. There is relative sparing of extraocular and bulbar muscles. CARCINOMA, SMALL CELL of the lung is a frequently associated condition, although other malignancies and autoimmune diseases may be associated. Muscular weakness results from impaired impulse transmission at the NEUROMUSCULAR JUNCTION. Presynaptic calcium channel dysfunction leads to a reduced amount of acetylcholine being released in response to stimulation of the nerve. (From Adams et al., Principles of Neurology, 6th ed, pp 1471)Endocrine System: The system of glands that release their secretions (hormones) directly into the circulatory system. In addition to the ENDOCRINE GLANDS, included are the CHROMAFFIN SYSTEM and the NEUROSECRETORY SYSTEMS.

*  Treatment of Zollinger-Ellison Syndrome - Full Text View -
Syndrome. Zollinger-Ellison Syndrome. Gastrinoma. Disease. Pathologic Processes. Paraneoplastic Endocrine Syndromes. ... Paraneoplastic Syndromes. Neoplasms. Gastrointestinal Neoplasms. Digestive System Neoplasms. Digestive System Diseases. ... In patients with Zollinger-Ellison Syndrome the level of gastric acid is elevated. This increased level of gastric acid is what ... It will also be possible to evaluate the effectiveness of histamine H2-receptor in patients with Zollinger-Ellison syndrome ...
*  Nexium Capsules Clinical Experience Investigation - Full Text View -
Paraneoplastic Endocrine Syndromes. Paraneoplastic Syndromes. Neoplasms. Gastrointestinal Neoplasms. Digestive System Neoplasms ... Zollinger-Ellison Syndrome. Gastrinoma. Pathologic Processes. Esophageal Diseases. Gastrointestinal Diseases. Digestive System ... Number of Adverse Drug Reactions [ Time Frame: Patients with gastric ulcer, anastomotic ulcer or Zollinger-Ellison syndrome: 8 ... Gastric Ulcer, Duodenal Ulcer, Anastomotic Ulcer, Reflux Oesophagitis,'Non-erosive Reflux Disease, Zollinger-Ellison Syndrome ...
*  Henzen C[au] - PubMed - NCBI
Paraneoplastic endocrine syndrome].. Henzen C.. Rev Med Suisse. 2016 Jan 27;12(503):230-1. German. No abstract available. ...
*  Lung Cancer
Paraneoplastic endocrine syndromes occur when the tumor produces hormones. The three most common are ectopic Cushing's syndrome ... Lambert-Eaton myasthenic syndrome is the most common of the neurologic paraneoplastic syndromes and is present in 3% of small ... Other paraneoplastic neurologic syndromes include cancer-associated retinopathy and the Lambert-Eaton myasthenic syndrome. In ... Other paraneoplastic syndromes include skeletal and connective tissue syndromes (clubbing, hypertrophic pulmonary ...
*  Paraneoplastic Syndromes - Hematology and Oncology - Merck Manuals Professional Edition
Endocrine paraneoplastic syndromes. The endocrine system is often affected by paraneoplastic syndromes. ... Neurologic paraneoplastic syndromes. Several types of peripheral neuropathy are among the neurologic paraneoplastic syndromes. ... Up to 20% of cancer patients experience paraneoplastic syndromes, but often these syndromes are unrecognized. ... Paraneoplastic Syndromes By Bruce A. Chabner, MD, Director of Clinical Research;Professor of Medicine, Massachusetts General ...
*  adrenal glands
Paraneoplastic Endocrine Syndromes. 2. + + +. 51. Carcinoma. 2. + + +. 52. Carcinoma, Renal Cell. 2. + + +. ...
*  Acromegaly Publications and Abstracts |
Endocrine paraneoplastic syndromes result from the production of bioactive substances from neoplastic cells, of endocrine or ... In endocrine paraneoplastic syndromes the secretion of peptides, amines or other bioactive substances is always ectopic and not ... is a syndrome characterized by hyperplasia of endocrine organs and may present with clinical features of Cushing syndrome and ... Acromegaly is a systemic syndrome caused by overproduction of growth hormone. Cutaneous, endocrine, cardiovascular, skeletal, ...
*  Dual paraneoplastic syndromes in a patient with small cell lung cancer: a case report | Journal of Medical Case Reports | Full...
Sequential paraneoplastic endocrine syndromes in small-cell lung cancer. J Clin Oncol. 2005, 23: 1312-1314. 10.1200/JCO.2005.01 ... Although paraneoplastic syndromes occur commonly, dual paraneoplastic syndromes occurring simultaneously in the same patient ... SCLC is the most common cancer histology associated with paraneoplastic syndromes. Paraneoplastic syndromes are divided into ... Although rare, there have been reports in the literature of patients with two or more paraneoplastic syndromes involving SCLC [ ...
*  Rare Cancer News & Clinical Trials » PubMed - Neuroendocrine Tumor
Endocrine paraneoplastic syndromes result from the production of bioactive substances from neoplastic cells, of endocrine or ... In endocrine paraneoplastic syndromes the secretion of peptides, amines or other bioactive substances is always ectopic and not ... The most common endocrine paraneoplastic syndromes are based on the secretion of antidiuretic hormone (ADH) resulting in ... Paraneoplastic endocrine syndromes mainly occur in highly malignant tumors; however, the development of these tumors does not ...
*  Paraneoplastic Syndromes: Endocrinologic/Hematologic | Harrison's Hematology and Oncology, 3e | AccessHemOnc | McGraw-Hill...
Many hormones are produced at low levels from a wide array of tissues in addition to the classic endocrine source. Thus, ... "Paraneoplastic Syndromes: Endocrinologic/Hematologic." Harrison's Hematology and Oncology, 3e Longo DL. Longo D.L. Ed. Dan L. ... Paraneoplastic syndromes is the term used to refer to the disorders that accompany benign or malignant tumors but are not ... Jameson J, Longo D.L. Jameson, J. Larry, and Dan L. Longo.Paraneoplastic Syndromes: Endocrinologic/Hematologic. In: Longo DL. ...§ionid=141422455
*  Small Cell Lung Cancer Treatment & Management: Approach Considerations, Combination Chemotherapy, Chemotherapy Dose Intensity...
Table 1. Paraneoplastic Syndromes Affecting Endocrine and Neurologic Function in SCLC Organ System Syndrome Mechanism Frequency ... Table 1. Paraneoplastic Syndromes Affecting Endocrine and Neurologic Function in SCLC. *Table 2. AJCC TNM Categories for Lung ... Tumor lysis syndrome. Tumor lysis can occur rapidly in patients with SCLC on institution of chemotherapy, especially in cases ... Syndrome of inappropriate ADH (SIADH) is reported in 5-10% of patients with SCLC. The serum sodium level is usually less than ...
*  Paraneoplastic syndrome - Wikipedia
Subscription required (help)). Paraneoplastic endocrine syndromes at the US National Library of Medicine Medical Subject ... may relate to paraneoplastic syndromes. Diagnostic testing in a possible paraneoplastic syndrome depends on the symptoms and ... "Background of Paraneoplastic Syndromes". "Etiology of Paraneoplastic syndromes". Dalmau, Josep; Rosenfield, Myrna R (December 6 ... In the case of paraneoplastic Cushing's syndrome arising from a small cel carcinoma of the endometrium, paraneoplastic syndrome ...
*  p ӭM ?? (SCLC) - | ??R P w - GII
Table 1: Symptoms of Neurologic and Endocrine Paraneoplastic Syndromes in SCLC *Table 2: AJCC TNM Classification System for ...
*  Metastatic Breast Cancer - Cancer Therapy Advisor
... endocrine paraneoplastic syndromes occur less commonly than neurologic syndromes). ... Rarely, patients can have symptoms arising from paraneoplastic syndromes (including cerebellar degeneration, opsoclonus- ... Commonly used endocrine therapies.. Drug. Class. Dose/Schedule. Associated toxicities. Tamoxifen. ER modulator. 20mg PO daily. ... Superior vena cava syndrome. Consider steroids and treat with radiation therapy. In specific cases a stent can be considered. ...
*  Lung cancer - Wikipedia
... which give this tumor an endocrine/paraneoplastic syndrome association.[69] Most cases arise in the larger airways (primary and ... "Paraneoplastic neurological syndromes". Orphanet Journal of Rare Diseases. BioMed Central. 2 (1): 22. doi:10.1186/1750-1172-2- ... Depending on the type of tumor, paraneoplastic phenomena-symptoms not due to the local presence of cancer-may initially attract ... leading to Horner's syndrome (dropping of the eyelid and a small pupil on that side), as well as damage to the brachial plexus. ...
*  List of MeSH codes (C04) - Wikipedia
... paraneoplastic endocrine syndromes MeSH C04.588.322.525 --- parathyroid neoplasms MeSH C04.588.322.609 --- pituitary neoplasms ... multiple endocrine neoplasia type 2b MeSH C04.700.635.220 --- denys-drash syndrome MeSH C04.700.635.950 --- wagr syndrome MeSH ... paraneoplastic syndromes, nervous system MeSH C04.588.614.550.225 --- lambert-eaton myasthenic syndrome MeSH C04.588.614.550. ... gardner syndrome MeSH C04.700.630.500 --- multiple endocrine neoplasia type 1 MeSH C04.700.630.505 --- multiple endocrine ...
*  Paraneoplastic Syndrome|Causes|Symptoms|Treatment|Pathogenesis|Types
Know what is paraneoplastic syndrome, its causes, symptoms, types, treatment and pathogenesis. Also know the common cancers ... Paraneoplastic syndrome is a set of sign and symptoms, which develop at distant sites from a tumor/cancer. ... Endocrine Paraneoplastic Syndrome: Paraneoplastic syndrome also affects the endocrine system. Patients having small cell cancer ... Pathogenesis of Paraneoplastic Syndrome. The pathogenesis of Paraneoplastic Syndrome is not clear. Paraneoplastic Syndrome can ...
*  Low-Grade Esthesioneuroblastoma Presenting as SIADH: A Review of Atypical Manifestations
... and insulin represent the most common endocrine substances produced in paraneoplastic syndromes. We found 14 reports of ENB ... Very rarely, ENBs present with symptoms that are associated with paraneoplastic syndromes, such as our patient. These syndromes ... L. C. Pelosof and D. E. Gerber, "Paraneoplastic syndromes: an approach to diagnosis and treatment," Mayo Clinic Proceedings, ... J. Yu, C. A. Koch, A. Patsalides et al., "Ectopic cushing's syndrome caused by an esthesioneuroblastoma," Endocrine Practice, ...
*  Endocrine Therapies in Breast Cancer - Aman U. Buzdar - Oxford University Press
Paraneoplastic Syndromes. Robert B. Darnell and Jerome B. Posner * Cancer and the Kidney. Second Edition ... You are here: Home Page , Medicine & Health , Radiology , Clinical Oncology , Endocrine Therapies in Breast Cancer ... Endocrine Therapies in Breast Cancer. Edited by Aman U. Buzdar. Oxford Oncology Library. *Summarizes the latest evidence-based ... 7. Combined endocrine and chemotherapy, Professor Aman U. Buzdar. 8. Hormonal replacement therapy in patients with prior ...
*  One Week Comparison Study of PTH and PTHrP Infusions - Full Text View -
Paraneoplastic Syndromes. Endocrine System Diseases. Bone Diseases, Endocrine. Bone Diseases, Metabolic. Musculoskeletal ... Endocrine System Diseases. MusculoSkeletal System Disease. Hormones. Postmenopausal Women. Bone metabolism. Physiologic ... Osteoporosis Hypercalcemia of Malignancy Hyperparathyroidism Bone Diseases, Endocrine Drug: Parathyroid Hormone-related Protein ... Subjects with cardiac, vascular, renal (serum creatinine , 1.5), pulmonary, endocrine, musculoskeletal, hepatic, hematologic, ...
*  The AnarchAngel : Whoever's writing this script... please call my office, I'd like to make some changes
I have a variant of multi-endocrine neoplasia, with associated paraneoplastic syndrome, but not likely one of the variants that ... into my other endocrine glands) probable.. At one point, my care team thought I may be able to get away without radiation... ... that I have one of the nastier variants of multi-endocrine neoplasia, which was thought to be a possibility. ...
*  Paraneoplastic Syndromes - Robert B. Darnell; Jerome B. Posner - Oxford University Press
Paraneoplastic syndromes, defined in this book as disorders caused by cancer, but not a direct result of cancer invasion of the ... SYSTEMIC SYNDROMES (WITH NEUROLOGIC IMPLICATIONS). INTRODUCTION. ENDOCRINE SYNDROMES. Cushing Syndrome Hypercalcemia SIADH ... Neurologic Paraneoplastic Syndromes Nonneurologic Paraneoplastic Syndromes. MELANOMA. URINARY TRACT CANCERS. Renal Cancers ... RHEUMATOLOGIC SYNDROMES. Arthropathy Fasciitis. AUTOIMMUNE SYNDROMES. Lupus Scleroderma Raynaud's Syndrome Digital Ischemia ...

(1/57) Recurrence of adrenal aldosterone-producing adenoma.

Conn's syndrome (adrenal aldosterone-producing adenoma) and bilateral adrenal hyperplasia are the most common causes of primary aldosteronism. The treatment of choice for patients with aldosterone-producing adenoma is unilateral total adrenalectomy. Recurrence after adequate surgery is exceptional. We present a patient with recurrence of an aldosterone-producing adenoma in the right adrenal gland 9 years after adenomectomy of a aldosterone-producing adenoma in the same adrenal gland. We conclude that adenomectomy is not an adequate therapy for patients with adrenal aldosterone-producing adenoma.  (+info)

(2/57) The differentiation of primary hyperparathyroidism from the hypercalcemia of malignancy.

The presence of hypercalcemia in patients with known cancers may be due to the cancers themselves, or to co-existing primary hyperparathyroidism. The differentiation of primary hyperparathyroidism from the hypercalcemia of malignancy is important since the relief of distressing symptoms and prevention of hypercalcemic crises and renal failure can be accomplished relatively easily by parathyroid surgery in the former condition, and only with difficulty, at times, with fluids and drugs in the latter condition. The histories of three recent patients are presented, which demonstrate the difficulties inherent in the differentiation of these conditions. These patients were ultimately found at operation to have primary hyperparathyroidism in addition to malignancies of the cervix, adrenal gland and kidney. In our experience the following have been helpful in establishing a diagnosis; history of hypercalcemia prior to development of cancer, the type of cancer itself, the effect of cancer therapy on the hypercalcemia, and selective venous sampling with radioimmunoassay for parathyroid hormone.  (+info)

(3/57) Guanosine nucleotides inhibit different syndromes of PTHrP excess caused by human cancers in vivo.

There are two well-described syndromes caused by tumor production of parathyroid hormone-related peptide (PTHrP), namely osteolytic bone disease associated with breast cancer and humoral hypercalcemia of malignancy (HHM) that occurs with or without bone metastasis. Both syndromes have been shown experimentally to be inhibited by neutralizing antibodies to PTHrP. In a search for small-molecule inhibitors of PTHrP production or effects, we have identified guanine-nucleotide analogs as compounds that inhibit PTHrP expression by human tumor cells associated with these syndromes. We show in nude athymic murine models that these compounds reduce PTHrP-mediated osteolytic lesions associated with metastatic human breast-cancer cells as well as the degree of hypercalcemia caused by excessive PTHrP production by a squamous-cell carcinoma of the lung. These results suggest that the PTHrP gene promoter may be a suitable target for treating the skeletal effects of malignancy.  (+info)

(4/57) Ectopic TSH-secreting pituitary adenoma of the vomerosphenoidal junction.

OBJECTIVE: We describe an unusual case of ectopic TSH-secreting pituitary adenoma arising from the vomerosphenoidal junction. CLINICAL PRESENTATION: A 52-Year-old man with a long-standing history of hyperthyroidism was referred to the University Hospital in September 2001 because of increasingly disabling symptoms of nasal obstruction. For the past 18 Years the patient had complained of palpitations, hypertension, weight loss, and nervousness. A presumptive diagnosis of Graves' disease was made. Treatment with methimazole was begun, but the patient was lost to follow-up. On admission, physical examination revealed signs of hyperthyroidism and a large diffuse goiter. Tests of thyroid function showed inappropriate secretion of TSH with hyperthyroidism. Both a TSH-secreting pituitary adenoma and resistance to thyroid hormone could be taken into account. There was no evidence of pituitary tumour by magnetic resonance imaging (MRI), but a large space-occupying lesion involving the nasal cavity and the nasopharynx was incidentally discovered. INTERVENTATION AND TECHNIQUE: Using an endoscopic endonasal approach, the tumour was removed en bloc together with the sphenoid floor, sphenoid rostrum, bony septum, and part of the soft palate mucosa. Histological features and immunophenotype were those of a TSH-secreting tumour. CONCLUSION: Although exceedingly rare, ectopic TSH-secreting pituitary tumour should be borne in mind in cases of inappropriate secretion of TSH with hyperthyroidism and no evidence of pituitary tumour by computed tomography and/or MRI when a mass located along the migration path of the Rathke's pouch is demonstrated by radiological examination. To our knowledge, this is only the second reported case in the literature.  (+info)

(5/57) Symptomatic epidural lipomatosis in ectopic Cushing's syndrome.

We report a case of spinal epidural lipomatosis (SEL) caused by ectopic Cushing's syndrome and give a review of the literature. The most common cause of SEL is prolonged therapy with glucocorticoids, only a very few cases are related to endogenous Cushing's syndrome. The pathophysiological mechanism is not clear but there is a possible role for the autonomic nervous system in the stimulation of growth of epidural fat. Severe neurological symptoms which indicate myelopathy and radiculopathy can occur, but there is often a delay in diagnosis because the non-specific initial symptoms are not recognized. The epidural fat is mostly located in the thoracic and lumbar region. Magnetic resonance imaging can establish the diagnosis rapidly. In patients with severe neurological symptoms, surgical decompression of the myelum and removal of the epidural fat is the treatment of choice. Most patients have partial or complete recovery of neurological deficits after surgical treatment or after discontinuing glucocorticoid therapy; mild cases can also be treated conservatively. Routine imaging for the detection of epidural-located lipomatosis in patients at risk is probably useful.  (+info)

(6/57) [18F]fluoro-2-deoxy-D-glucose ([18F]FDG) positron emission tomography imaging of thymic carcinoid tumor presenting with recurrent Cushing's syndrome.

We report a case of a young woman with Cushing's syndrome (CS), in whom although endocrine investigations and negative pituitary imaging were suggestive of ectopic ACTH secretion, the results of inferior petrosal sinus (IPS) sampling after coricotropin-releasing hormone (CRH) stimulation were suggestive of pituitary ACTH hypersecretion. (111)In-labelled octreotide and high-resolution computer tomography (CT) revealed a lesion possibly responsible for the ACTH source in the thymus. Thymectomy confirmed concomitant ectopic CRH and probable ACTH production by a thymic neuroendocrine carcinoma. After an 8-year remission period the patient developed a clinical and biochemical relapse. A high-resolution computed tomography (CT) scan of the thorax showed a 2-cm nodule in the thymic bed, which was positive on a [(18)F]fluoro-2-deoxy-D-glucose ([(18)F]FDG) positron emission tomography (PET) scan. However, a repeated thymectomy did not result in remission. A repeat [(18)F]FDG PET study showed persistent disease in the thymic bed and also uptake in the adrenals. The patient underwent bilateral adrenalectomy, which resulted in clinical remission. A further [(18)F]FDG PET scan 8 months later showed no progression of the thymic tumor and confirmed complete excision of the adrenals. This is a rare case of concomitant CRH and ACTH secretion from a thymic carcinoid tumor; the case illustrates the usefulness of functional imaging with [(18)F]FDG PET in the diagnosis, management and follow-up of neuroendocrine tumors.  (+info)

(7/57) Mixed endocrine pancreatic tumors producing several peptide hormones.

Twenty-four endocrine pancreatic tumors were examined immunohistochemically for insulin, glucagon, gastrin and ACTH. In seven of these tumors, more than one peptide-hormone-containing cell type was observed. These seven tumors were also examined with conventional staining methods for the presence of A1, A2, and B cells. The results showed that these staining methods do not always distinguish between the different hormone-producing cell types of endocrine pancreatic tumors. In spite of the fact that several types of hormone-secreting cells were found in the tumors, the case histories described symptoms characteristic of hypersecretion of only one of the hormones. The hormone of the predominating cell type could not always explain the clinical symptoms. Our results indicate the endocrine pancreatic tumors often are multihormonal. Therefore, it would seem advisable to screen serum from all insuloma patients for a variety of peptide hormones.  (+info)

(8/57) ACTH-secreting 'apudoma' of gallbladder.

The case of a 44-year-old woman is reported. The diagnosis after the appropriate tests and laparotomy was ACTH-secreting 'apudoma' of the gallbladder. This is a rare tumour and this case is believed to be the first reported of an ectopic hormone producing tumour from this side.  (+info)

  • cortisol
  • The excess cortisol may also affect other endocrine systems and cause, for example, insomnia, inhibited aromatase, reduced libido, impotence in men, and amenorrhoea/oligomenorrhea and infertility in women due to elevations in androgens. (
  • Zollinger-Ellison
  • In patients with Zollinger-Ellison Syndrome the level of gastric acid is elevated. (
  • This protocol describes the use of histamine H2-receptor antagonists to control gastric acid hypersecretion in patients with Zollinger-Ellison syndrome. (
  • It will also be possible to evaluate the effectiveness of histamine H2-receptor in patients with Zollinger-Ellison syndrome after successful gastrinoma resection who continue to have mild gastric hypersecretion. (
  • H2-Histamine receptor blocking agents in the Zollinger-Ellison syndrome. (
  • Patients treated with Nexium for the first time due to gastric ulcer, duodenal ulcer, anastomotic ulcer, reflux oesophagitis, non-erosive reflux disease, Zollinger-Ellison syndrome. (
  • immune system depression
  • Mucocutaneous dysfunctions of paraneoplastic syndromes can be seen in cases of itching (hypereosinophilia), immune system depression (latent varicella-zoster virus in sensory ganglia), pancreatic tumors (leading to adipose nodular necrosis of subcutaneous tissues, flushes (prostaglandin secretions), and even dermic melanosis (cannot be eliminated via urine and results in grey to black-blueish skin tones). (
  • benign
  • Acanthosis nigricans is conventionally divided into benign and malignant forms, although may be divided into syndromes according to cause: Benign This may include obesity-related, hereditary, and endocrine forms of acanthosis nigricans. (
  • It delineates acanthosis nigricans syndromes according to their associated syndromes, including benign and malignant forms, forms associated with obesity and drugs, acral acanthosis nigricans, unilateral acanthosis nigricans, and mixed and syndromic forms. (
  • Tumors
  • Tumors in the top of the lung , known as Pancoast tumors , may invade the local part of the sympathetic nervous system , leading to Horner's syndrome (dropping of the eyelid and a small pupil on that side), as well as damage to the brachial plexus . (
  • causes
  • Postural orthostatic tachycardia syndrome (POTS) is a condition in which a change from lying to standing causes an abnormally large increase in heart rate. (
  • chronic
  • There is significant overlap between POTS and chronic fatigue syndrome, with evidence of POTS in 25-50% of CFS cases. (
  • common
  • Careful studies of the prevalence of paraneoplastic syndromes indicate that they are more common than is generally appreciated. (
  • The most common endocrinologic and hematologic syndromes associated with underlying neoplasia will be discussed here. (
  • A trifecta of POTS, EDS, and Mast Cell Activation Syndrome (MCAS) is becoming increasingly more common, with a genetic marker common among all three conditions. (